Viral safety measures of plasma for transfusion and applicability in Spain;Medidas de seguridad viral del plasma destinado a transfusión y su aplicación en España

Medicina Clinica

Volumn 129, Issue 12, 2007, Pages 458-468

  Pereira, Arturo ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; FRESH FROZEN PLASMA; METHYLENE BLUE; PROTHROMBIN; PSORALEN; RIBOFLAVIN;

BLEEDING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR DEFICIENCY; BLOOD TRANSFUSION; CANCER RISK; GENOTOXICITY; GEOGRAPHIC DISTRIBUTION; HEART SURGERY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LIVER TRANSPLANTATION; NONHUMAN; PHOTOOXIDATION; PHOTOTOXICITY; PLASMA; PLASMAPHERESIS; PUVA; REVIEW; SPAIN; SURGICAL PATIENT; TREATMENT INDICATION; TREATMENT OUTCOME; ULTRAVIOLET IRRADIATION; VIRUS INACTIVATION; VIRUS TRANSMISSION;

EID: 36048946689     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13111004     Document Type: Article

References (78)

1. Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risk of blood transfusions. JAMA. 2003;289:959-62.
2. Álvarez M, González R, Hernández JM, Oyonarte S. Residual risk of transfusion-transmited vírica infections in Spain, 1997-2002, and impact of nucleic acid testing. Euro Surveill. 2005;10:20-2.
3. Ministerio de Sanidad y Consumo. Estadística Estatal de Centros de Transfusión [documento electrónico] [citado Dic 2006]. Disponible en: http://www.msc.es/profesionales/saludPublica/medicinaTransfusional/ indicadores/docs/evolucionEstadistica_2005.pdf
4. Wallis JP, Wells AW, Matthews JN, Chapman CE. Long-term survival after blood transfusion: a population based study in the North of England. Transfusion. 2004;44:1025-32.
5. Pereira A, Sanz C. A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols. Transfusion. 2000;40:1182-91.
6. Pereira A. Health and economic impact of posttransfusion hepatitis B and cost-effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union. Transfusion. 2003;43:192-201.
7. Ministerio de Sanidad y Consumo. Vigilancia epidemiológica del VIH en España: actualización año 2005 [documento electrónico] [citado Dic 2006]. Disponible en: http://193.146.50.130/ htdocs/sida/nuevos_diagnosticos_ccaa.pdf
8. Bruguera M, Forns X. Hepatitis C en España [revisión]. Med Clin (Barc). 2006;127:113-7.
9. Pereira A. Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion. 1999;39:479-87.
10. Jackson BR, AuBuchon JP, Birkmeyer JD. Update of cost-effectiveness analysis for solvent-detergent-treated plasma [carta]. JAMA. 1999; 282:329.
11. Stanworth SJ, Brunskill SJ, Hyde CJ, Murphy MF, McClelland DBL. Appraisal of the evidence for the clinical use of FFP and plasma fractions. Best Pract Res Clin Haematol. 2006;19:67-82.
12. Hellstern P. Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol. 2004;11:346-50.
13. Solheim BG, Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apher Sci. 2006;35:83-90.
14. Pelletier JPR, Transue S, Snyder EL. Pathogen inactivation techniques. Best Practice & Research Clin Haematol. 2006;19:205-42.
15. Coignard BP, Nguyên G, Tokars J, McMillan M, Mascola L, Jarvis W. A cluster of intra-operative deaths in a liver transplant center associated with the use of solvent/detergent plasma - California 2000. Epidemic Intelligence Service 50th annual conference. Center for Disease Control and Prevention [documento electrónico] [citado Ene 2007]. Disponible en: www.cdc.gov/eis/conference/archives/2001Program.pdf
16. FDA. 2002 safety alerts for drugs, biologicals, medical devices, and dietary supplements. MedWatch [Documento electrónico] [citado Ene 2007]. Disponible en: www.fda.gov/medwatch/safety/2002/safety02.htm#plas+
17. Gradis D. Doctors are cautioned not to give a type of plasma to liver patients. The New York Times, 11 de mayo de 2002.
18. Hellstern P, Larbig E, Walz GA, Thürigen W, Oberfrank K. Prospective study on efficacy and tolerability of solvent/detergent-treated plasma in intensive care unit patients. Infusionsther Transfusionsmed. 1993;20 Suppl 2:16-8.
19. Inbal A, Epstein O, Blickstein D, Kornbrot N, Brenner B, Martinowitz U. Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and aacquired coagulation disorders. Blood Coagul Fibrinolysis. 1993;4:599-604.
20. Horowitz MS, Pehta JC. SD plasma in TTP and coagulation factor deficiencies for which no concentrates are available. Vox Sang. 1998;SV:231-5.
21. Williamson LM, Llewelyn CA, Fisher NC, Allain JP, Bellamy MC, Baglin TP, et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion. 1999;39:1227-34.
22. Beck KH, Mortelmans Y, Kretschmer V, Höltermann W, Lukasewitz P. Comparison of solvent/detergent-inactivated plasma and fresh frozen-plasma under routine clinical conditions. Infusionsther Transfusionsmed. 2000;27:144-8.
23. Lerner RG, Nelson J, Scorcia E, Grima K, Kancherla RR, Zarou-Naimo CM, et al. Evaluation of solvent/detergent plasma in patients with prolonged prothrombin time. Vox Sang. 2000;79:161-7.
24. Haubelt H, Blome M, Kiessling AH, Isgro F, Bach J, Saggau W, et al. Effects of solvent/detergent-treated plasma and fresh frozen plasma on hemostasis and fibrinolysis in complex coagulopathy following open-heart surgery. Vox Sang. 2002;82:9-14.
25. De Jonge J, Groenland THN, Metsellar HJ, Ijzermans JNM, Van Vliet HHDM, Visser L, et al. Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP®). Anesth Analg. 2002;94:1127-31.
26. Tollofsrud S, Noddeland H, Svennevig JL, Bentse G, Mollnes TE, Solheim BG. Universal fresh frozen plasma (Uniplas): a safe product in open-heart surgery. Intensive Care Med. 2003;29:1736-43.
27. Santagostino E, Mancuso ME, Morfini M, Schiavoni M, Tagliaferri A, Barillari G, et al. Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: doping, pharmacokinetics and clinical efficacy. Haematologica. 2006;91:634-9.
28. Chekrizova V, Murphy WG. Solvent-detergent plasma: use in neonatal patients, in adult and paediatric patients with liver disease and in obstetric and gynaecological emergencies. Transfus Med. 2006;16:85-91.
29. Flamholz R, Jeon HR, Baron JM, Baron BW. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep vein thrombosis? J Clin Apher. 2000; 15:169-72.
30. Murphy K, O'Brien P, O'Donnell J. Acquired protein-S deficiency in thrombotic thrombocytopenic purpura patients receiving solvent/detergent plasma exchange [carta]. Br J Haematol. 2003;122:518-9.
31. Yarranton H, Cohen H, Pavord SR, Benjamin S, Hagger D. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol. 2003:121:778-85.
32. Wagner SJ. Virus inactivation in blood components by photoactive phenothiazine dyes [revision]. Transfus Med Rev. 2002;16:61-6.
33. Williamson LM, Cardigan R, Prowse CV. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety? [revisión]. Transfusion. 2003;43:1322-9.
34. Lambrecht B, Möhr H, Knuver-Hopf J, Schmitt H. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang. 1991;60:207-13.
35. Simonsen AC, Sorensen H. Clinical tolerance of methylene blue virus inactivated plasma. Vox Sang. 1999;77:210-7.
36. Hornsey VS, Drummond O, Young D, Docherty A, Prowse CV. A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-Tronic system. Transfus Med. 2001;11:31-6.
37. Garwood M, Cardigan RA, Drummond O, Hornsey VS, Turner CP, Young D, et al. The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma. Transfusion. 2003;43:1238-47.
38. Gutter B, Speck WT, Rosenkranz HS. A study of the photoinduced mutagenicity of methylene blue. Mutat Res. 1977;44:177-82.
39. McBride TJ, Schneider JE, Floyd RA, Loeb LA. Mutations induced by methylene blue plus light in single-stranded M13mp2. Proc Natl Acad Sci. 1992;89:6866-70.
40. Wagner SJ, Cifone MA, Murli H, Dodd RY, Myhr B. Mammalian genotoxicity assessment of methylenen blue in plasma: implications for viral inactivation. Transfusion. 1995;35:407-13.
41. Tiboni GM, Lamonaca D. Transplacental exposure to methylene blue initiates teratogenesis in the mouse: preliminary evidence for a mechanistic implication of cyclic GMP pathway disruption. Teratology. 2001;64:213-20.
42. Cragan JD. Teratogen update: methylene blue. Teratology. 1999;60:42-8.
43. Olliver JR, Wild CP, Sahay P, Dexter S, Hardie LJ. Chromoendoscopy with methylene blue and associated DNA damage in Barrett's oesophagus. Lancet. 2003;362:373-4.
44. Harvey JW, Keitt AS. Studies of the efficacy and potential hazards of methylene blue therapy in aniline-induced methaemoglobinaemia. Br J Haematol. 1983;54:29-41.
45. Gillman PK. Methylene blue implicated in potentially fatal serotonin toxicity [carta]. Anaesthesia. 2006;61:1013-4.
46. Porat R, Gilbert S, Magilner D. Methylene blue-induced phototoxicity: an unrecognized complication. Pediatrics. 1996;97:717-21.
47. Sills MR, Zinkham WH. Methylene blue-induced Heinz body hemolytic anemia. Arch Pediatr Adolesc Med. 1994;148:306-10.
48. Dewachter P, Mouton-Faivre C, Tréchot P, Lleu J-C, Mertes PM. Severe anaphylactic shock with methylene blue instillation. Anesth Analg. 2005;101:149-50.
49. Levi M, De Jonge E, Van der Poll. Plasma and plasma components in the management of disseminated intravascular coagulation. Best Practice & Research Clin Haematol. 2006;19:127-42.
50. Erber WN, Perry DJ. Plasma and plasma products in the treatment of massive haemorrhage. Best Practice & Research Clin Haematol. 2006;19:97-112.
51. Inada Y, Hessel B, Blomback B. Photooxidation of fibrinogen in the presence of methylene blue and its effects on polymerization. Biochem Biophys Acta. 1978;532:161-70.
52. Suontaka A-M, Blombäck M, Chapman J. Changes in functional activities of plasma fibrinogen after treatment with methylene blue and red light. Transfusion. 2003;43:568-75.
53. Depasse F, Sensebé L, Seghatchian J, Andreu G, Samama MM. The influence of methylene blue light treatment and methylene blue removal filter on fibrinogen activity states and fibrin polymerisation indices. Transfus Apher Sci. 2005;33:63-9.
54. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis. 2002;22:83-96.
55. Zeiler T, Riess H, Wittmann G, Hintz G, Zimmermann R, Müller C, et al. The effect of methylene blue phototreatment on plasma proteins and in vitro coagulation capacity of single-donor fresh-frozen plasma. Transfusion. 1994;34:685-9.
56. Atance R, Pereira A, Ramírez B. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion. 2001;41:1548-52.
57. De la Rubia J, Arriaga F, Linares D, Larrea L, Carpio N, Marty ML, et al. Role of methylene blue-treated plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol. 2001;114:721-3.
58. Álvarez-Larrán A, del Río J, Ramírez C, Albo C, Peña F, Campos A, et al. Methylene blue-photoinactivated plasma vs fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang. 2004;86:246-51.
59. Del Rio J, Álvarez-Larrán A, Martínez C, De la Rubia J, Zamora C, Muncunill J, et al. Plasma fotoinactivado con azul de metileno (PFIAM) y plasma fresco congelado cuarentenado (PFC) en el tratamiento de la púrpura trombótica trombocitopénica (PTT) idiopática: datos preliminares de un estudio multicéntrico prospectivo observacional [resumen]. XLVIII Reunión Nacional de la AEHH. Granada, octubre de 2006.
60. Wollowitz S. Fundamentals of the psoralene-based HelinxTM technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol. 2001;38 Suppl 11:4-11.
61. Anónimo. Cerus Corporation anuncia aprobación normativa en Europa para el sistema sanguíneo para plasma INTERCEPT. Yahoo Finanzas, 22 de noviembre de 2006 [documento electrónico] [citado Ene 2007]. Disponible en: http://es.biz.yahoo.com/061122/182/5797p.html
62. Lindelöf B, Sigurgeirsson B, Tegner E, Larkö O, Johannesson A, Berne B, et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol. 1999;141:108-12.
63. Ciaravino V. Preclinical safety of a nucleid acid-targeted HelinxTM compound: a clinical perspective. Semin Hematol. 2001;38 Suppl 11:12-9.
64. Ciaravino V, McCullogh T, Cimino G, Sullivan T. Preclinical safety profile of plasma prepared using the INTERCEPT blood system. Vox Sang. 2003;85:171-82.
65. Van Rhenen D, Gullikson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H, et al. Transfusion of pooled buffy coat platelet components with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood. 2003;101:2426-33.
66. Snyder E, McCullough J, Slichter S, Strauss RG, Lopez-Plaza I, Lin J-S, et al. Clinical safety profile of platelets treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion. 2005;45:1864-75.
67. Singh Y, Sawyer LS, Pinkoski LS, Dupuis KW, Hsu JC, Lin L, et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivated pathogens while retaining coagulation function. Transfusion. 2006;46:1168-77.
68. Hambleton J, Wages D, Radu-Radulescu L, Adams M, MacKenzie M, Shafer S, et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion. 2002;42: 1302-7.
69. De Alarcon P, Benjamin R, Dugdale M, Kessler C, Shopnick R, Smith P, et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion. 2005;45: 1362-72.
70. Mintz PD, Bass NM, Petz LD, Steadman R, Streiff M, McCullough J, et al. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood. 2006;107: 3753-60.
71. Mintz PD, Neff A, MacKenzie M, Goodnough LT, Hillyer C, Kessler C, et al. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thormbocytopenic purpura. Transfusion. 2006;46:1693-704.
72. Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci. 2006;35:5-17.
73. Orden 1998/13741 del Ministerio de Sanidad y Consumo de 2 de junio. BOE 139 (11 de junio de 1998):19293-4.
74. Real Decreto 1088/2005 de 16 de septiembre. BOE 225 (20 de septiembre de 2005):31288-304.
75. Mascaró M, Muncunill J, Sedeño M, Jiménez MT, Girona E, Rigo P. Yield of a program of plasma quarantine [Resumen]. Transfusion. 2003; 43 Suppl:116A.
76. Ordre de 24 de desembre de 1996 del Departament de Sanitat i Seguretat Social. Diari oficial de la Generalitat de Catalunya 2321 (31 de enero de 1997):1117-8.
77. Ordre de 27 de novembre de 1997 del Departament de Sanitat i Seguretat Social. Diari oficial de la Generalitat de Catalunya 2547 (30 de diciembre de 1997):15080.
78. Epstein JS, Vostal JG. FDA approach to evaluation of pathogen reduction technology [editorial]. Transfusion. 2003;43:1347-50.